Although reported cases of mpox in the United States have significantly declined since the outbreak peak in the summer of 2022, small clusters have continued to occur.

Severe Mpox manifestations, including deaths, also continue to occur. The Centers for Disease Control and Prevention (CDC) strongly encourages providers, health departments, and community-based organizations to remain diligent about taking their patients sexual history and recommending the two-dose JYNNEOS vaccine to those who are eligible to help reduce the risk of continued Mpox transmission. The vaccine is FDA-approved and is safe and effective in preventing or minimizing the severity of Mpox.

Mpox Update: Stay Up to Date on Testing, Treatment, and Vaccination. Clinical Outreach and Communication Activity (COCA) Call. May 18, 2023.https://emergency.cdc.gov/coca/calls/2023/callinfo_051823.asp

Clinical Recognition. Key Characteristics for Identifying Mpox. August 30, 2023. Centers for Disease Control and Prevention (CDC).Clinical Recognition | Mpox | Poxvirus | CDC